{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Kidney+Disease+Requiring+Hemodialysis&page=2",
    "query": {
      "condition": "Chronic Kidney Disease Requiring Hemodialysis",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Kidney+Disease+Requiring+Hemodialysis&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:05:46.221Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01322347",
      "title": "Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure Chronic Requiring Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Soluble Ferric Pyrophosphate (SFP)",
          "type": "DRUG"
        },
        {
          "name": "Standard dialysate",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Rockwell Medical Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 294,
      "start_date": "2011-04",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-26",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 38,
      "location_summary": "Paragould, Arkansas • Pine Bluff, Arkansas • Alhambra, California + 31 more",
      "locations": [
        {
          "city": "Paragould",
          "state": "Arkansas"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01322347"
    },
    {
      "nct_id": "NCT03988270",
      "title": "Prefistula Forearm Exercise in Pts Requiring Chronic HD Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Arterio-venous Fistula",
        "Kidney Failure",
        "Hemodialysis Access Failure"
      ],
      "interventions": [
        {
          "name": "Exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2019-06-17",
      "completion_date": "2021-11-09",
      "has_results": false,
      "last_update_posted_date": "2022-01-10",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03988270"
    },
    {
      "nct_id": "NCT01015313",
      "title": "Effects of Intensified Sodium Management in Hemodialysis Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Renal Failure Chronic Requiring Hemodialysis"
      ],
      "interventions": [
        {
          "name": "intensive sodium management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Renal Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-11",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2015-10-01",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 3,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01015313"
    },
    {
      "nct_id": "NCT04523220",
      "title": "Study to Investigate the Safety of a Drug Called Osocimab at Low and High Doses in Adult Patients With Kidney Failure Requiring Regular Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End-stage Renal Disease",
        "Prevention of Thromboembolic Events",
        "Hemodialysis",
        "Hemodiafiltration"
      ],
      "interventions": [
        {
          "name": "BAY1213790 (Osocimab)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 704,
      "start_date": "2020-08-28",
      "completion_date": "2022-05-30",
      "has_results": true,
      "last_update_posted_date": "2023-07-21",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 26,
      "location_summary": "Azusa, California • Brawley, California • Encino, California + 21 more",
      "locations": [
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Brawley",
          "state": "California"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04523220"
    },
    {
      "nct_id": "NCT00086164",
      "title": "Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hyperplasia",
        "Chronic Renal Failure"
      ],
      "interventions": [
        {
          "name": "edifoligide (E2F Decoy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anesiva, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": null,
      "start_date": "2004-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-07-19",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • Hudson, Florida • Miami, Florida + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hudson",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00086164"
    },
    {
      "nct_id": "NCT05908084",
      "title": "To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "End Stage Renal Disease (ESRD)"
      ],
      "interventions": [
        {
          "name": "Acellular Tissue Engineered Vessel (ATEV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AVF",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Humacyte, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2023-09-07",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 32,
      "location_summary": "Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "El Centro",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05908084"
    },
    {
      "nct_id": "NCT04511338",
      "title": "Feasibility Study for Heparin-free Hemodialysis With the Dialyzer With Endexo™",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Diseases",
        "Patient Requiring Heparin Free Dialysis Treatments"
      ],
      "interventions": [
        {
          "name": "Dialyzer with Endexo",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Fresenius Medical Care North America",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-11-02",
      "completion_date": "2021-06-16",
      "has_results": true,
      "last_update_posted_date": "2022-03-04",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 2,
      "location_summary": "New Bern, North Carolina",
      "locations": [
        {
          "city": "New Bern",
          "state": "North Carolina"
        },
        {
          "city": "New Bern",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511338"
    },
    {
      "nct_id": "NCT04032613",
      "title": "Breaking Down Care Process and Patient-level Barriers to Arteriovenous Access Creation Prior to Hemodialysis Initiation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Chronic Kidney Disease Requiring Chronic Dialysis"
      ],
      "interventions": [
        {
          "name": "Vascular Access Navigation and Education Quality Improvement Program",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2019-07-30",
      "completion_date": "2020-06-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 1,
      "location_summary": "Danville, Pennsylvania",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032613"
    },
    {
      "nct_id": "NCT04534114",
      "title": "Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease Requiring Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Fesomersen sodium (BAY2976217)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 307,
      "start_date": "2020-09-04",
      "completion_date": "2022-05-12",
      "has_results": true,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 9,
      "location_summary": "Clovis, California • Victorville, California • Fort Lauderdale, Florida + 5 more",
      "locations": [
        {
          "city": "Clovis",
          "state": "California"
        },
        {
          "city": "Victorville",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Saint Ann",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04534114"
    },
    {
      "nct_id": "NCT02414204",
      "title": "Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Improve Endothelial Function and Decrease Vascular Stenosis"
      ],
      "interventions": [
        {
          "name": "Sildenafil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "19 Years to 99 Years"
      },
      "enrollment_count": 4,
      "start_date": "2015-04",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-08-12",
      "last_synced_at": "2026-05-22T04:05:46.221Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02414204"
    }
  ]
}